◎ Sugi Atlas

Atlas / Disease / Zygomycosis

Zygomycosis

disease
On this page

Also known as MucormycosisZygomycota infectious disease

Summary

Zygomycosis (MONDO:0019136) is a disease and 19 clinical trials. Top therapeutic interventions include amphotericin b, deferasirox, and isavuconazole. A subtype of opportunistic mycosis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

  • Prevalence: Unknown (Worldwide)
  • Phenotypes (HPO): 76
  • Clinical trials: 19

Clinical features

Signs & symptoms

Clinical features (HPO)

76 HPO clinical features (Orphanet curated; top 50 by frequency):

HPO IDTermFrequency
HP:0000246SinusitisFrequent (30-79%)
HP:0001945FeverFrequent (30-79%)
HP:0012378FatigueFrequent (30-79%)
HP:0012531PainFrequent (30-79%)
HP:0012735CoughFrequent (30-79%)
HP:0032162Unusual skin infectionFrequent (30-79%)
HP:0000572Visual lossOccasional (5-29%)
HP:0000622Blurred visionOccasional (5-29%)
HP:0000629Periorbital fullnessOccasional (5-29%)
HP:0000819Diabetes mellitusOccasional (5-29%)
HP:0001291Abnormal cranial nerve morphologyOccasional (5-29%)
HP:0001622Premature birthOccasional (5-29%)
HP:0001742Nasal congestionOccasional (5-29%)
HP:0001875Decreased total neutrophil countOccasional (5-29%)
HP:0001993KetoacidosisOccasional (5-29%)
HP:0002013VomitingOccasional (5-29%)
HP:0002014DiarrheaOccasional (5-29%)
HP:0002018NauseaOccasional (5-29%)
HP:0002027Abdominal painOccasional (5-29%)
HP:0002105HemoptysisOccasional (5-29%)
HP:0002107PneumothoraxOccasional (5-29%)
HP:0002113Pulmonary infiltratesOccasional (5-29%)
HP:0002202Pleural effusionOccasional (5-29%)
HP:0002248HematemesisOccasional (5-29%)
HP:0002315HeadacheOccasional (5-29%)
HP:0002383Infectious encephalitisOccasional (5-29%)
HP:0002583ColitisOccasional (5-29%)
HP:0004377Hematological neoplasmOccasional (5-29%)
HP:0004387EnterocolitisOccasional (5-29%)
HP:0005263GastritisOccasional (5-29%)
HP:0008066Abnormal blistering of the skinOccasional (5-29%)
HP:0011949Acute infectious pneumoniaOccasional (5-29%)
HP:0031417RhinorrheaOccasional (5-29%)
HP:0032166Unusual gastrointestinal infectionOccasional (5-29%)
HP:0032172Air crescent signOccasional (5-29%)
HP:0032177Parenchymal consolidationOccasional (5-29%)
HP:0032564IleitisOccasional (5-29%)
HP:0032674Cutaneous woundOccasional (5-29%)
HP:0045026Abnormality of the mediastinumOccasional (5-29%)
HP:0100537FasciitisOccasional (5-29%)
HP:0100539Periorbital edemaOccasional (5-29%)
HP:0100658CellulitisOccasional (5-29%)
HP:0100721Mediastinal lymphadenopathyOccasional (5-29%)
HP:0100749Chest painOccasional (5-29%)
HP:0100750AtelectasisOccasional (5-29%)
HP:0200035Skin plaqueOccasional (5-29%)
HP:0200039PustuleOccasional (5-29%)
HP:0000083Renal insufficiencyVery rare (<1-4%)
HP:0000123NephritisVery rare (<1-4%)
HP:0000265MastoiditisVery rare (<1-4%)

Identifiers

Disease identifiers

FieldValue
Canonical nameZygomycosis
Mondo IDMONDO:0019136
EFOEFO:0007380
MeSHD009091, D020096
Orphanet73263
DOIDDOID:8485
ICD-10-CMB46
ICD-111676389165
NCITC77212
SNOMED CT59277005, 76627001
UMLSC0043541
MedGen12207
GARD0010224
MedDRA10028098, 10061418
NORD1946
Is cancer (heuristic)no

Also known as: Mucormycosis · mucormycosis · Zygomycota infectious disease

Disease family

This is a subtype of opportunistic mycosis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › opportunistic mycosis › Zygomycosis

Related subtypes (11): phaeohyphomycosis, candidiasis, maple bark strippers’ lung, aspergillosis, cryptococcosis, geotrichosis, microsporidiosis, fusariosis, pneumocystosis, opportunistic systemic mycosis, hyalohyphomycosis

Subtypes (1): basidiobolomycosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

1 approved drug — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

DrugStatus
Amphotericin BApproved (phase 4)

2 drugs in clinical trials for this disease (phase 2–3, investigational): efficacy not established — a trial record, not an indication.

DrugHighest phase
DeferasiroxPhase 2
PosaconazolePhase 2

Clinical trials & evidence

Clinical trials

Clinical trials: 19.

Phase distribution (across all retrieved trials)

PhaseTrials
Not specified17
PHASE22

Top trials by phase / activity

NCTPhaseStatusTitle
NCT00419770PHASE2COMPLETEDThe Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study
NCT00467883PHASE2COMPLETEDPilot Study of High Dose Liposomal Amphotericin B Efficacy in Initial Zygomycosis Treatment
NCT05406037Not specifiedRECRUITINGBiomarkers for Invasive Mucormycosis
NCT06440915Not specifiedRECRUITINGStudy on Theraputic Drug Monitoring and Phamacokinetics of Isavuconazole in Children
NCT06515743Not specifiedACTIVE_NOT_RECRUITINGRehabilitation With an Obturator in Maxillary Defects
NCT06878144Not specifiedNOT_YET_RECRUITINGMucormycosis Clinical Core for the MUCOR-ADVANCE P01 Project
NCT07080359Not specifiedNOT_YET_RECRUITINGIsavuconazole in Critically Ill Patients: Efficacy and Safety
NCT07191756Not specifiedACTIVE_NOT_RECRUITINGAmphotericin B Versus Isavuconazole for Mucormycosis: A Comparative Efficacy and Safety Study
NCT02845934Not specifiedCOMPLETEDProspective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis
NCT03387696Not specifiedCOMPLETEDMucormycosis in ICU
NCT04550936Not specifiedCOMPLETEDA Study to Understand How the Use of Paxlovid Affected the Healthcare Use in People With Pre-existing Conditions.
NCT04744454Not specifiedCOMPLETEDPost Marketing Surveillance (PMS) Study of Cresemba in Korea.
NCT04935463Not specifiedCOMPLETEDMucormycosis in COVID-19
NCT05074043Not specifiedCOMPLETEDCOVID-19 Associated Mucormycosis: A Multidisciplinary Dilemma in Assiut University Hospital
NCT05097664Not specifiedUNKNOWNOcular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran
NCT05212961Not specifiedCOMPLETEDCOVID-19 and Rhino-orbital Mucormycosis
NCT05348434Not specifiedCOMPLETEDEvaluation of Using 3D Printed PEEK Facial Implants in Repairing Maxillofacial Deformities
NCT05925660Not specifiedUNKNOWNMucorales PCR Screening in At-risk Hematology Patients
NCT06900114Not specifiedCOMPLETEDDisease Burden Transition of Mucormycosis in Hematologic Malignancies Population Across Covid 19 Era: a Single-center Comparative Analysis From China

Drugs tested across these trials (top 30)

MoleculeMax phaseTrials referencing
AMPHOTERICIN B41
DEFERASIROX41
ISAVUCONAZOLE34

About this page

Generated deterministically by Sugi Atlas from primary biomedical databases via BioBTree. Every record on this page traces to a primary source.

Generated
Atlas version
v1.1.4
BioBTree
v2.0.2

Sources 25

This page pulls from 25 datasets indexed by BioBTree:

chembl_moleculecivic_evidenceclinical_trialsclinvardoidefogardgenccgwasgwas_studyhgncicd10cmicd11meddramedgenmeshmimmondomondochildmondoparentncitnordorphanetsctidumls